MitoLab

Mitolab is a research-driven MedTech company specializing in precision mitochondrial medicine and immune-metabolic rehabilitation. Our core innovation, the Mito-Passport technology, is a first-of-its-kind diagnostic and therapeutic framework based on the assessment of the mitochondrial conglomerates - functional networks dynamics within immune cells.

Key Assets & Capabilities:

• Proprietary Methodology: Advanced analysis of mitochondrial functional ensembles in neutrophils as systemic biosensors.

• Proven Clinical Track Record: Our protocols have demonstrated a 26.7% reduction in regional cancer mortality and a 40% decrease in chemotherapy-induced toxicity.

• Clinical Base: Direct partnership with the Military Clinical Hospital (Extracorporeal Detoxification Unit) for high-load clinical validation.

• Expertise: Deep integration of molecular biophysics, clinical toxicology, and onco-rehabilitation.

Mitolab serves as an ideal industrial partner for MSCA Doctoral Networks, providing a unique environment for translational research, access to validated clinical databases, and state-of-the-art facilities for mitochondrial-guided therapy development